PFF Teal = 0+160+175 MAIN COLORS PFF Green = 120+162+47 Light Green = 193+216+47 Red = 242+102+73 HIGHLIGHT COLORS Light Grey = 220+220+210 Dark Grey =

Slides:



Advertisements
Similar presentations
Diagnostic tools – imaging and lung function (humans)
Advertisements

Idiopathic pulmonary fibrosis (IPF) – The need for early recognition and referral PRC-2128.
Interstitial lung disease in systemic sclerosis
Coinvolgimento polmonare nella sclerosi sistemica Marco Matucci Cerinic Departments of Rheumatology AVC BioMedicine & Division of Rheumatology AOUC Medicine,
Case of combined pulmonary fibrosis with emphysema(CPFE) and its importance to recognize Abstract ID
Lung biopsy in fibrosing ILD Does it have value? Athol Wells, Royal Brompton Hospital, London UK.
Clinical Approaches to IPF: Diagnosis and Monitoring Kevin R. Flaherty, MD, MS Associate Professor Pulmonary and Critical Care Medicine University of Michigan.
INTERSTITIAL LUNG DISEASE
IDIOPATHIC PULMONARY FIBROSIS
THE DIAGNOSIS OF IPF Steven A. Sahn, MD
IDIOPATHIC PULMONARY FIBROSIS
Early detection of pulmonary involvement in scleroderma patients By Mohamed Mostafa Metwally, MD, FCCP Assistant professor of chest diseases Assiut University.
Esam H. Alhamad, M.D Assistant Professor of Medicine Consultant Pulmonary & Critical Care Medicine.
BAL in the diagnosis of ILD Athol Wells Royal Brompton Hospital London, UK.
OFEV ® (nintedanib) TOMORROW trial results Last updated These slides are provided by Boehringer Ingelheim for medical to medical education only.
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
Pulmonary Fibrosis Foundation Summit 2015
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
History : 52-year-old male presented with a left testicular mass. An initial chest radiograph was performed, followed by a CT. Question : What are the.
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
R1 정수웅.  Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause that occurs.
Should it be viewed as a single entity? Hypersensitivity pneumonitis Should it be viewed as a single entity? Venerino Poletti versus Athol Wells.
Ganesh Raghu, Harold R. Collard, Jim J. Egan, Fernando J. Martinez, Juergen Behr, Kevin K. Brown et al on behalf of the ATS/ERS/JRS/ALAT Committee on Idiopathic.
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis N ENGL J MED. May 18, /NEJMoa Talmadge E. King, Jr., M.D.,
Clinical Tools for the Primary Care Physician. Objectives Raise the clinical index of suspicion for ILD in patients presenting with the hallmark signs.
Management of Idiopathic Pulmonary Fibrosis in the Elderly Patient [ CHEST JULY 2015 ] 호흡기내과 R4. 박세정.
Usual interstitial pneumonia: an overview Ola El-Zammar, M.D. Assistant professor of pathology SUNY Upstate Medical University, Syracuse, NY.
CHEST 2013; 144(1):234–240 R1 정수웅 Christopher J. Ryerson, MD ; Thomas Hartman, MD ; Brett M. Elicker, MD ; Brett Ley, MD ; Joyce S. Lee, MD ; Marta Abbritti,
Emerging Approaches to Treatment of IPF Gregory P. Cosgrove, MD Associate Professor, Pulmonary Division Assistant Director, Interstitial Lung Disease Program.
IPF Diagnostic Methods and Differential Diagnosis
Department of Respiratory Medicine
Recent Advances in Idiopathic Pulmonary Fibrosis
Subjects characteristics
NSIP subtypes Dominique Valeyre Paris 13 University
Demystifying Idiopathic Pulmonary Fibrosis
Patient with IPF and no honeycombing on HRCT
News at the horizon Concepts of clinical behaviour in the ILDs
To treat or not to treat? IPF and preserved lung function
Progressive Fibrosing Interstitial Lung Diseases – Addressing the Challenges Concept of Progressive Fibrosing ILDs With Examples.
831_ePAT CARE: Patient case Dr. Molina Dr
The Role of Imaging in Diagnosing IPF Hands-On Case Studies
Respiratory MCNs - Interstitial lung diseases
Patient Demographics Referred by:
Name: Age: Sex: Presenting History Symptom progression Current status:
Patient with FVC>90% predicted
Filming: 15th of Febuary 2016, London, UK
Kaplan–Meier survival curves of interstitial pneumonia with autoimmune features (IPAF) with usual interstitial pneumonia (UIP) pattern (on high-resolution.
Multidisciplinary Perspectives on Interstitial Lung Diseases
Changes in high-resolution computed tomography (HRCT) pattern over time. a) Idiopathic pulmonary fibrosis (IPF), increased specificity over time. Changes.
MTX Lung vs. Rheumatoid Lung Disease
Chronic Obstructive Pulmonary Disease: An Evidence-Based Approach to Treatment With a Focus on Anticholinergic Bronchodilation  Nicholas J. Gross, MD,
Interstitial lung disease
Rheumatoid Arthritis-Associated Interstitial Lung Disease
Imaging to Assess IPF Progression A Case-Based Approach
Kaplan–Meier survival curves of all-cause mortality in patients with idiopathic pulmonary fibrosis (IPF). Kaplan–Meier survival curves of all-cause mortality.
Extent of interstitial lung disease (ILD) in patients with systemic sclerosis-associated ILD. A simple stratification that utilises pulmonary function.
Patient case study 2—fibrotic uILD in the setting of IPAF
Change in forced vital capacity (FVC) % predicted (% pred) per week from baseline in the CAPACITY 004 and 006 study comparing pirfenidone (2403 mg·day−1)
COUNTERPOINT: Does Interstitial Pneumonia With Autoimmune Features Represent a Distinct Class of Patients With Idiopathic Interstitial Pneumonia? No 
New Models of Care in Idiopathic Pulmonary Fibrosis
Early Diagnosis and Management of SSc-ILD
IPF diagnosis: flexibility is a virtue
Working Together to Diagnose Idiopathic Pulmonary Fibrosis
Subtypes of ILD in pre-MDT and post-MDT cohorts.
Diagnostic algorithm for idiopathic pulmonary fibrosis (IPF).
Presentation transcript:

PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey = Black = APPROVED DRUGS FOR IPF: SHOULD THEY BE STUDIED FOR NON-IPF PULMONARY FIBROSIS? KEVIN K. BROWN, MD CLINICAL CARE: NEW AND EVOLVING TREATMENT STRATEGIES NOVEMBER 14, 2015

Yes

Questions to consider: 1. Are we treating a single disease, a syndrome or a pathologic mechanism that manifests as progressive pulmonary fibrosis? 2. Is the treatment safe in the population? 3. Is the treatment efficacious in the population?

In 2015 the diagnosis of IPF requires: 1. Exclusion of other known causes of interstitial lung disease (e.g., domestic exposures, connective tissue disease, and drug toxicity). 2. The presence of a UIP chest imaging pattern on HRCT in patients not subjected to surgical lung biopsy. 3. Specific combinations of HRCT chest imaging patterns and pathologic patterns in patients who undergo a surgical lung biopsy.

Screen failures in the recent Pirfenidone trial

Comparison of Selected Inclusion/Exclusion Criteria

Not performed UIP Probable UIP Possible UIP Not UIP UIPIPF Not IPF Possible UIP Unclassifiable IPF Some are IPF, some are not Not IPF Inconsist- ent with UIP Unclassifiable Some are IPF, some are not Not IPF Lung Biopsy HRCT Not IPF per guidelines IPF per guidelines ASCEND INPULSIS Courtesy: Hal Collard

The Problem with Chest Imaging

Trial Design Comparison: ASCEND vs. CAPACITY

Measuring Agreement Among Observers Kappa ValueStrength of Agreement < 0Poor 0–0.2Slight 0.2–0.4Fair 0.4–0.6Moderate 0.6–0.8Substantial 0.8–1.0Almost perfect Sackett DL, et al. Clinical Epidemiology: A basic science for clinical medicine; 1991:29. Landis JR, Koch GG. Biometrics. 1977;33: Clinically useful agreement Actual Agreement Beyond Chance Potential Agreement Beyond Chance Kappa = =

Inter-observer Variation among Radiologists Median (range)  w coefficient of agreement IPF0.63 (0.48 – 0.78) NSIP0.51 (0.27 – 0.78) Sarcoidosis0.70 (0.58 – 0.84) Extrinsic allergic alveolitis0.60 (0.36 – 0.78) COP0.49 (0.06 – 0.76) Smoking related ILD0.51 (0.20 – 0.73) Aziz ZA et al, Thorax 2004 For CT diagnosis of pulmonary embolus Kappa = For CT diagnosis of cystic lung disease Kappa =

The Presence of Honeycombing on HRCT  = 0.31 ( )  = 0.21 ( ) Agreement among experts and study site Agreement among expert readers Lynch et al, Am J Respir Crit Care Med 2005

The Presence of Honeycombing on HRCT  = 0.31 ( )  = 0.21 ( ) Agreement among experts and study site Agreement among expert readers Lynch et al, Am J Respir Crit Care Med 2005

Agreement on the Presence of a UIP Pattern Lynch et al, Am J Respir Crit Care Med 2005  = 0.33 ( ) Agreement among expert readers

Thomeer M et al, Eur Respir J 2008

Weighted Kappa Among HRCT Reviewers Thomeer M et al, Eur Respir J 2008

Weighted Kappa Among HRCT Reviewers Thomeer M et al, Eur Respir J 2008

The Problem with Pathology

Kappa coefficients (k) between lobar and final diagnoses in 48 patients DiagnosisLobar diagnosis (n = 98) Final diagnosis (n = 48) UIP0.40 Moderate0.49 Moderate NSIP0.32 Fair OP HP Sarcoidosis Normal0.07N/A Overall0.39 Fair0.43 Moderate Nicholson AG et al, Thorax. 2004

Weighted Kappas Among 2 Pathologists Nicholson AG et al, Thorax. 2004

NSIP vs. UIP

Jegal. Am J Respir Crit Care Med 2005; 171:639 P=0.007 Kaplan-Meier survival curves of subjects with IPF and fibrotic NSIP

FVC change > 10% p=0.01 Flaherty, Am J Resp Crit Care Med, 2003 Change in FVC predicts survival in IPF and NSIP

Jegal. Am J Respir Crit Care Med 2005; 171:639 Change in FVC predict survival in IPF and NSIP

Baseline Predictors of Survival Jegal et al, Am J Respir Crit Care Med 2005

Predictors of Survival at 6 Months Jegal et al, Am J Respir Crit Care Med 2005

Predictors of Survival at 6 Months Jegal et al, Am J Respir Crit Care Med 2005

IPF vs. Fibrotic HP

UIP NSIP CIP or OP Ohtani et al, Thorax 2005 Pathologic Pattern predicts mortality in HP

Vourlekis et al, Am J Med 2004 Fibrosis predicts mortality in HP p = median survival 7.1 yrs median survival > 20 yrs

Hanak et al, Chest 2008 Presence of CT Fibrosis predicts survival

IPF Mortality is related to CT Disease Extent 3 / 8 (38%) 23 / 93 (25%) 17 / 179 (9%) 1 / 35 (3%) Disease Extent Mortality (%) Lynch et all, Am J Respir Crit Care Med 2005

Extent of CT Fibrosis predicts survival in HP Hanak et al, Chest 2008

Olson et al, Chest 2008

Survival is shortened in RA Solomon JJ et al, Resp Med 2013

ExRA shortens survival in RA Solomon JJ et al, Resp Med 2013

ILD shortens survival in RA Solomon JJ et al, Resp Med 2013

Fibrotic ILD shortens survival in RA Solomon JJ et al, Resp Med 2013

Survival with RA-UIP is Similar to IPF Solomon JJ et al, Resp Med 2013

Moua T et al, Resp Res 2014

Strand et al, Chest 2014 Idiopathic Pulmonary Fibrosis (IPF)

Connective Tissue Disease-UIP Strand et al, Chest 2014

Corte T, et al 2012 Eur Respir 39:

Moua T et al, Mayo Clin Proc 2014 Positive serologies in IPF have no impact on mortality

Park et al, Chest 2007

AE-PF Clinical context and Prognosis Huie et al, Respirology 2010 Underlying Diagnosis IPF CTD-ILD UIP pattern RA UCTD NSIP pattern UCTD SSc Dermatomyositis LIP Drug-induced ILD Unclassified

IPF-like IPF Probable IPF Not IPF IP-AF Fibrotic HP fNSIP ARDS Possible IPF Sarcoidosis CTD-ILD

The diagnosis of IPF remains a challenge and many IPF patients do not meet our current diagnostic criteria The presence of fibrosis in the setting of IPAF, connective tissue disease, and hypersensitivity pneumonitis is associated a similar clinical course and early mortality It is the presence of progressive pulmonary fibrosis that is the problem The rationale and opportunity to study the safety and efficacy of current IPF therapy in non-IPF pulmonary fibrosis exists and is compelling Summary